
Vaxess co-founders (L-R): Livio Valenti, Michael Schrader, and Kathryn Kosuda (Credit: Vaxess)
Exclusive: AstraZeneca and Vaxess developing skin patch mRNA vaccines for pandemic flu
AstraZeneca is developing a novel type of mRNA vaccine that can be administered as a shelf-stable skin patch instead of a shot, potentially making distribution …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.